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Abstract
AIM
To evaluate the role of small bowel capsule endoscopy 
(SBCE) on the reclassification of colonic inflammatory 
bowel disease type unclassified (IBDU).
Retrospective Study
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METHODS
We performed a multicenter, retrospective study including 
patients with IBDU undergoing SBCE, between 2002 and 
2014. SBCE studies were reviewed and the inflammatory 
activity was evaluated by determining the Lewis score 
(LS). Inflammatory activity was considered significant and 
consistent with Crohn’s disease (CD) when the LS ≥ 135. 
The definitive diagnosis during follow-up (minimum 12 mo 
following SBCE) was based on the combination of clinical, 
analytical, imaging, endoscopic and histological elements.
RESULTS
Thirty-six patients were included, 21 females (58%) with 
mean age at diagnosis of 33 ± 13 (15-64) years. The 
mean follow-up time after the SBCE was 52 ± 41 (12-156) 
mo. The SBCE revealed findings consistent with significant 
inflammatory activity in the small bowel (LS ≥ 135) in 
9 patients (25%); in all of them the diagnosis of CD was 
confirmed during follow-up. In 27 patients (75%), the 
SBCE revealed no significant inflammatory activity (LS < 
135); among these patients, the diagnosis of Ulcerative 
Colitis (UC) was established in 16 cases (59.3%), CD 
in 1 case (3.7%) and 10 patients (37%) maintained a 
diagnosis of IBDU during follow-up. A LS ≥ 135 at SBCE 
had a sensitivity = 90%, specificity = 100%, positive 
predictive value = 100% and negative predictive value = 
94% for the diagnosis of CD.
CONCLUSION
SBCE proved to be fundamental in the reclassification of 
patients with IBDU. Absence of significant inflammatory 
activity in the small intestine allowed exclusion of CD in 
94% of cases.
Key words: Inflammatory bowel disease; Inflammatory 
bowel disease type unclassified; Capsule endoscopy; 
Crohn’s disease; Lewis score; Reclassification
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This is a retrospective study to evaluate the 
role of small bowel capsule endoscopy (SBCE) on the 
reclassification of colonic inflammatory bowel disease 
type unclassified (IBDU). The SBCE revealed findings 
consistent with significant inflammatory activity in the 
small bowel, Lewis score (LS) ≥ 135, in 9 patients (25%); 
in all of them the diagnosis of Crohn’s disease (CD) was 
confirmed during follow-up. In 27 patients (75%) without 
significant inflammatory activity (LS < 135), the diagnosis 
of ulcerative colitis was established in 16 cases (59.3%), 
CD in 1 case (3.7%) and 10 patients (37%) maintained a 
diagnosis of IBDU during follow-up.
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MJ, Pinho R, Mascarenhas Saraiva M, Cotter J. Essential role 
of small bowel capsule endoscopy in reclassification of colonic 
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Endosc 2017; 9(1): 34-40  Available from: URL: http://www.
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INTRODUCTION
The differential diagnosis of Crohn’s disease (CD) and 
ulcerative colitis (UC) relies on a combination of clinical, 
analytical, imaging, endoscopic and histologic data[1,2]. 
In 5% of patients with inflammatory bowel disease 
limited to the colon is not possible to establish a definitive 
diagnosis into CD or UC[3]. In 1978, Price introduced 
the concept of indeterminate colitis to describe cases in 
which colonic resections had been undertaken for chronic 
inflammatory bowel disease but a definitive diagnosis 
of either of UC and CD was not possible[4]. In 2005, 
the Montreal Working Party proposed that the term 
“indeterminate colitis” should be reserved for patients in 
whom surgical specimen is available and the term “colonic 
IBD type unclassified” (IBDU) for patients with no 
surgical specimen available and for whom the endoscopy 
is inconclusive and histology reveals chronic inflammation 
with absence of definite diagnostic features of either CD 
or UC[5]. Actually, for most patients, IBDU represents a 
temporary diagnosis, as it has been estimated that 80% 
of them will be reclassified to either CD or UC within 8 
years[6].
The correct diagnosis of inflammatory bowel disease 
is extremely important to define prognosis, therapeutic 
orientation and surgical intervention[7,8]. Since Small 
Bowel Capsule Endoscopy (SBCE) enables a direct 
endoscopic visualization of throughout the small intestine 
with higher diagnostic yield compared to conventional 
endoscopy or imaging studies[9,10], it may be expected 
to contribute for the reclassification of IBDU. We report 
a multicenter study that aimed to evaluate the role of 
SBCE to reclassify patients with IBDU. 
MATERIALS AND METhODS
We performed a multicenter study including consecutive 
patients undergoing SBCE between 2002 and 2014 for 
IBDU, ASCA negative/pANCA negative.
All patients had undergone an ileocolonoscopy prior 
to SBCE. Inclusion criteria were as follows: Patients 
with clinical features of chronic IBD, without previously 
known small bowel involvement, in whom endoscopic 
type and/or distribution of lesions did not allow a definite 
diagnosis of CD or UC, microscopy indicating active and 
patchy transmucosal chronic inflammation with minimal 
or moderate architectural distortion and absence of 
unequivocal diagnostic features for either CD or UC, after 
exclusion of infectious colitis[5]. Subjects were excluded 
from entering the study if they had nonsteroidal anti-
inflammatory drugs intake within 4 wk prior to capsule 
endoscopy[11], clinical or imaging evidence of bowel 
stenosis or occlusion, or a follow-up of less than 12 mo.
Patients underwent SBCE with PillCam® SB1/SB2/
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SB3 (Given® Imaging, Yoqneam, Israel), Endocapsule® 
(Olympus Medical Systems Corporation, Tokyo, Japan) 
or Mirocam® (Intromedic Co., Ltd., Seoul, South Korea) 
receiving a clear liquid diet the day before capsule 
ingestion and an overnight 12 h fast. No bowel purge was 
administered prior to capsule ingestion.
SBCE videos were reviewed by two experienced 
gastroenterologists in each center. In case of disa-
greement, the findings were reviewed by investigators 
until a consensus was reached. Inflammatory activity 
was objectively assessed by determining the Lewis score 
(LS)[12]. Inflammatory activity was considered significant 
and consistent with CD when the LS ≥ 135[13].
The mean, SD, and range were calculated for 
continuous data. Categorical data analysis was conducted 
using the Fisher exact test. Data analysis was performed 
using SPSS version 20.0 (IBM, Armonk, New York, United 
States). Test characteristics were determined using a 2 × 
2 table and calculating the sensitivity, specificity, positive 
predictive value and negative predictive value.
Statistical significance was considered when the P 
value was less than 0.05.
RESULTS
A total of 36 consecutive patients with IBDU underwent 
SBCE procedures between October 2002 and August 
2014, with a mean follow-up before the exam of 30 mo 
(1-108 mo). 
The mean age of patients at the time of diagnosis of 
IBDU and at time of SBCE was 33 years and 36 years, 
respectively, with 58% being of female gender. 
Table 1 summarizes the demographic and clinical 
characteristics of the study population. The capsule was 
ingested without difficulty by all of the 36 subjects. There 
were no cases of capsule retention or reported adverse 
events in any of the subjects included in this study.
A complete small-bowel examination was achieved 
in 97.2% of studies. The mean follow-up after SBCE was 
52 mo (12-156 mo).
At the moment of SBCE thirty four patients had 
clinically active disease and received anti-inflammatory 
treatment, as summarized in Tables 2 and 3. SBCE 
revealed small bowel lesions in 13 of patients (36.1%) 
and 23 (63.9%) patients had no lesions detected on 
SBCE. The distribution of the lesions in the small intestine 
were as follows: Two patients had multiple ulcerations 
(n ≥ 8) throughout the entire small bowel, 1 patients 
had ulcerations in first and second tertiles, 1 patient 
had ulcerations only in the second tertile, 5 patients had 
multiples ulcerations in the third tertile. In 4 patients 
the capsule revealed subtle findings of focal edema in a 
single short segment of the small bowel (Table 2).
Nine patients (25%) had inflammatory lesions con­
sidered significant (LS ≥ 135) and consistent with a 
diagnosis of CD (Table 2). In 4 of those patients (44.4%) 
a subsequent ileocolonoscopy showed, by this occasion, 
lesions compatible with CD in the terminal ileum and his-
tology of colonic lesions was unspecific. In the remaining 
5 patients (55.6%), the histology of colonic lesions was 
unspecific and ileoscopy detected no lesions.
In 27 patients (75%), the SBCE revealed no sig-
nificant inflammatory activity (LS < 135). Among these 
patients, no lesion was detected in 23 patients and subtle 
lesions were found in 4 cases (Tables 2 and 3).
One patient (4.3%) with no lesions at SBCE had on 
follow-up a subsequent ileoscopy which revealed lesions 
compatible with CD (Table 3).
In 12 of 23 patients (52.2%) with no lesions at 
SBCE, a diagnosis of UC was established on follow-up, 
on average 38.3 mo after SBCE (Table 3). Four patients 
(25%) with a final diagnosis of UC had subtle lesions 
(focal edema) on SBCE (Table 2). In all of these patients 
the endoscopic and histological findings were consistent 
with the diagnosis of UC, which remained in clinical and 
analytical remission on follow-up.
Ten patients (27.8%) remained with a diagnosis 
of IBDU after a mean follow-up of 42 mo (Table 3). 
Considering the endoscopic criterion of significant infla­
mmatory activity to predict a diagnosis of CD, using a 
cut-off for LS ≥ 135[13], it would result in no false positive 
and only one false negative examinations, corresponding 
to a sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) of 90%, 100%, 
100% and 94%, respectively.
In 6 of 9 patients (66.7%) with significant infla-
mmatory activity detected in SBCE, the treatment during 
the follow-up was escalated to immunosuppressive 
drugs or biological therapy (Table 2). In 3 of 16 (18.8%) 
patients with a definitive diagnosis of UC and in 4 of 10 
(40%) patients who remained with a diagnosis of IBDU 
on follow-up, a new IBD medication was introduced 
during the follow-up. 
The start of treatment with thiopurines and/or biologics 
in patients who were previously naïve to those medications 
Table 1  Demographics and clinical characteristics of the 
inflammatory bowel disease type unclassified patients
No. of patients, n (%) 36 (100)
Gender
  Female 21 (58.3)
  Male 15 (41.7)
Age (yr) (mean ± SD) at diagnosis   33.2 ± 13.1 (15-64)
Age (yr) (mean ± SD) at SBCE   35.9 ± 13.3 (18-64)
Device (no. patients), n (%)
PillCam® SB1 13 (36.1)
PillCam® SB2 16 (44.4)
PillCam® SB3   1 (2.8)
Mirocam®   5 (13.9)
Endocapsule®   1 (2.8)
Gastric transit time (min)   38.6 ± 44.7 (2–257)
Small bowel transit time (min) 290.4 ± 101.5 (52-480)
Incomplete SBCE   1 (2.8)
Capsule retention 0
Follow-up (mo) before SBCE   30.2 ± 29.9 (1-108)
Follow-up (mo) after SBCE   51.9 ± 40.5 (12-156)
IBDU: Inflammatory bowel disease type unclassified; SB: Small bowel; 
SBCE: Small bowel capsule endoscopy.
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occurred in 6/9 (66.7%) vs 5/27 (18.5%) patients with or 
without significant inflammatory activity detected at the 
SBCE, respectively (P = 0.012).
DISCUSSION
Ileocolonoscopy remains the first line exam to achieve the 
diagnosis in patients with suspected IBD[14]. Nonetheless, 
ileocolonoscopy can miss CD and result in false negative 
results due to skip lesions throughout the terminal 
ileum[15].
Upper endoscopy, SBCE, computed tomography 
enterography (CTE) and magnetic resonance entero-
graphy (MRE) can provide important information and may 
be useful to establish a definitive diagnosis[14].
In patients with suspected CD and negative ileocol-
onoscopy findings, recent European guidelines recommends 
SBCE as the next diagnostic exam for small bowel 
investigation, in the absence of obstructive symptoms or 
known stenosis[11].
SBCE has proven its superiority in identifying infla-
mmatory lesions consistent with the diagnosis of CD in 
the small intestine when compared to CTE[9,16] or MRE[10], 
thus it has assumed an important role on the evaluation 
of patients with suspected CD[13,17-19], having a high 
negative predictive value for the absence of significant 
Table 2  Clinical characteristics and outcome of the patients with positive small bowel capsule
Case Sex Age SBCE Findings LS Treatment pre-SBCE Treatment post-SBCE Diagnostic at follow-up
1 F 38 Multiple jejuno-ileal ulcerations 1404 5ASA 5 ASA + AZT CD
2 F 18 Ulcer (n = 1) and edema of 3° tertile 143 AZT Anti-TNF CD
3 M 23 Ulcer (n = 1) and edema of 3° tertile 143 5ASA 5ASA CD
4 F 20 Ulcerations (n = 2) and edema of 3° tertile 233 5ASA 5ASA CD
5 F 33 Ulcer (n = 3) of 2° tertile 225 5ASA 5ASA CD
6 F 19 Multiple ulcerations and edema of 3° tertile 908 5ASA AZT CD
7 M 60 Focal edema of 1° tertile 8 No treatment 5ASA UC
8 M 22 Multiple jejuno-ileal ulcerations 2080 5ASA 5ASA + AZT CD
9 F 32 Multiple ulcerations and edema of 3° tertile 908 5ASA AZT CD
10 F 27 Focal edema of 3° tertile 8 Prednisolone anti-TNF UC
11 F 47 Focal edema of 2° tertile 8 5ASA 5ASA UC
12 F 31 Ulceration and edema of 1° (n = 5) and 2° tertile (n = 6) 879 5ASA+Prednisolone AZT CD
13 M 44 Focal edema of 3º tertile 8 5ASA 5ASA UC
5ASA: Mesalamine; anti-TNF: Anti-tumor necrosis factor drug; AZT: Azathioprine; CD: Crohn’s disease; SBCE: Small bowel capsule endoscopy; LS: Lewis 
score; UC: Ulcerative colitis.
Table 3  Clinical characteristics and outcome of the patients with negative small bowel capsule
Case Sex Age Treatment pre-SBCE Treatment post-SBCE Diagnostic at follow-up
1 M 45 5ASA 5ASA IBDU
2 F 15 Prednisolone, 5ASA 5ASA UC
3 F 27 AZT, 5ASA AZT UC
4 F 26 5ASA 5ASA UC
5 M 31 5ASA 5ASA IBDU
6 F 34 5ASA 5ASA IBDU
7 M 21 5ASA 5ASA IBDU
8 F 22 5ASA 5ASA, AZT IBDU
9 F 56 5ASA 5ASA UC
10 F 27 AZT, anti-TNF AZT, anti-TNF UC
11 F 30 5ASA 5ASA UC
12 M 24 5ASA 5ASA CD
13 M 49 5ASA 5ASA UC
14 M 43 5ASA 5ASA UC
15 F 30 5ASA + AZT Anti-TNF IBDU
16 M 24 5ASA 5ASA UC
17 F 20 5ASA 5ASA UC
18 M 55 5ASA 5ASA IBDU
19 F 31 5ASA 5ASA, AZT, Anti-TNF UC
20 F 48 5ASA 5ASA, AZT IBDU
21 M 64 5ASA 5ASA UC
22 M 44 No treatment 5ASA IBDU
23 M 53 5ASA 5ASA IBDU
5ASA: Mesalamine; anti-TNF: Anti-tumor necrosis factor drug; AZT: Azathioprine; CD: Crohn’s disease; IBDU: Colonic 
inflammatory bowel disease type unclassified; SBCE: Small bowel capsule endoscopy; UC: Ulcerative colitis.
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inflammatory activity[13]. However, there is still limited 
evidence for the role of SBCE in patients with IBDU[11]. 
Most studies[20-22] used the non-validated diagnostic 
criteria for small-bowel CD proposed by Mow et al[23] 
(presence of more than three ulcerations).
Meanwhile, two scoring systems have been developed 
to standardize the quantification of inflammatory activity 
in the small bowel. The Capsule Endoscopy Crohn’s 
Disease Activity Index (CECDAI) is based on evaluation 
of the following parameters: Inflammation, extent of 
disease and presence of a stricture, while the LS eval-
uates villous appearance, ulcers and strictures[12]. The 
LS has shown a better performance than the CECDAI at 
describing small­bowel inflammation[24].
Indeed, LS has been shown a strong interobserver 
agreement for the determination of the inflammatory 
activity, and it is validated for the reporting small-bowel 
inflammatory activity[25,26].
In our study, the findings revealed by SBCE were 
consistent with a diagnosis of CD, based upon LS ≥ 135, 
in 9 of 36 (25%) of the subjects with IBDU, which is in 
line with the 16%-50% range described in other previous 
series[20-22,27-29]. An even higher percentage has been 
reported in pediatric patients[14].
In the present study, 4 patients (25%) with final 
diagnosis of UC had subtle small bowel lesions, such as 
focal edema, without a significant inflammatory activity, 
LS < 135, and with clinical and analytical remission during 
follow-up. Indeed, previous studies already reported a 
significantly higher frequency of small-bowel lesions in 
UC patients as compared with that in the control healthy 
volunteers[30]. The significance of the presence of these 
lesions and the possible risk of misdiagnosis is still 
indeterminate[31].
Although a negative SBCE study did not allow to 
definitely exclude a future diagnosis of small bowel CD, 
as further investigation and biopsies on follow-up led to a 
diagnosis of CD in one patient, the absence of significant 
inflammatory activity (LS < 135) in the small intestine 
actually allowed exclusion of CD in 94% of cases. 
Based on our findings, SBCE may lead to reclas-
sification of disease from suspected IBDU to definitive CD 
in 25% of cases. Furthermore, treatment with thiopurines 
and/or biologics was initiated more often in patients 
with significant inflammatory activity detected on SBCE 
(66.7% vs 18.5%, P = 0.012). This association suggests 
that capsule findings may be helpful in the clinical 
management of these patients, as already been proven in 
other series[28,32-34].
There are some limitations of this study, including 
its retrospective design, a limited number of subjects, 
and no direct comparison of SBCE with alternative small 
bowel diagnostic imaging, however, the last was not an 
aim of this study.
Nevertheless, to our knowledge this is one of the 
studies with larger number of patients included to evaluate 
this particular issue[20-22,27-29]. 
There are no definite diagnostic criteria for IBDU, as 
it must be considered a provisional diagnosis until more 
information (clinical, endoscopic, radiologic or pathologic ) 
or data on follow­up enable a definitive reclassification[35]. 
Mucosal biopsy samples before treatment can be useful 
to distinguish UC from CD, but this distinction is based 
primarily on the pattern, type and location (distribution) 
of the disease, rather than specific histological features, 
for which there is much overlap between the two 
diseases[36]. Therefore, SBCE has a valuable role in the 
reclassification of patients with IBDU, may also contribute 
to establish the strategy for clinical management, and 
should be performed in the undefined diagnosis, which 




Colonic inflammatory bowel disease type unclassified (IBDU) is defined as 
a chronic idiopathic inflammatory bowel disease limited to the colon, whose 
combination of clinical, analytical, imaging, endoscopic and histological 
elements does not allow a differential diagnosis between Crohn’s disease (CD) 
and ulcerative colitis.
Research frontiers
In patients with suspected CD and negative ileocolonoscopy findings, small 
bowel capsule endoscopy (SBCE) is the next diagnostic exam for small bowel 
investigation, in the absence of obstructive symptoms or known stenosis. 
Since SBCE enables a direct endoscopic visualization of throughout the small 
intestine, it may be expected to contribute for the reclassification of IBDU. 
However, the role of SBCE in IBDU has not been clearly established. In this 
study, the authors evaluate the role of SBCE on the reclassification of IBDU.
Innovations and breakthroughs
In this study, inflammatory activity on SBCE was objectively assessed by 
determining the Lewis score (LS). SBCE lead to reclassification of disease from 
IBDU to definitive CD in 25% of cases. Although a negative SBCE study did 
not allow to definitely exclude a future diagnosis of small bowel CD, as further 
investigation and biopsies on follow-up led to a diagnosis of CD in one patient, 
the absence of significant inflammatory activity (LS < 135) in the small intestine 
actually allowed exclusion of CD in 94% of cases. 
Applications
This study suggests that SBCE is useful in the reclassification of patients with 
IBDU. Facing a patient with IBDU, a SBCE should be performed in order to 
diagnosis or exclude a CD.
Peer-review
This manuscript “Essential role of small bowel capsule endoscopy in 
reclassification of colonic inflammatory bowel disease type unclassified” is well 
written. 
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